Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Inclusion Criteria: * Adult aged 20 or over and under 80 years of age * Those who satisfy the following conditions among chronic hepatitis B patients diagnosed with type 2 diabetes. first. For the first diagnosis of type 2 diabetes: 6.5% ≤ HbA1c \< 10.0%; second. Diagnosed with type 2 diabetes: HbA1c \< 10.0%; * Subjects who show significant liver fibrosis of 7 kilopascal or more in liver elasticity test using Fibroscan. * Subjects who voluntarily sign the informed consent form after understanding the clinical study and being informed of the risks and benefits. Exclusion Criteria: * Those who are currently taking Pioglitazone or Evogliptin, or those who have stopped taking medication for less than 4 weeks. * Patients meeting the criteria for alcoholic fatty liver (if alcohol intake exceeds 210 g per week for men and 140 g per week for women for the past 2 years) * Cirrhosis patients with decreased liver function (CTP class B and C) * Those taking drugs that can cause fatty liver (amiodarone, methotrexate, tamoxifen, valproate, corticosteroids, etc.) * Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis (within 24 weeks) * In case of allergy or hypersensitivity reaction to the target drug or its components. * Patients treated with oral or parenteral corticosteroids chronically (\>14 consecutive days) within 8 weeks prior to screening * Malnutrition, starvation, and debilitatin…